NMTC stock forecast, quote, news & analysis
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities... Show more
Why NeuroOne Medical Technologies (NMTC) Stock Is Down -21.5% in the Last 30 Days
Key Takeaways
- NMTC shares fell approximately 21.5% over the last 30 days, declining from about $1.12 to $0.88.
- The drop occurred despite a series of positive operational announcements, including revenue growth, new purchase orders, and clinical publications.
- Persistent net losses, cash burn, and investor concerns about a micro-cap medtech with an unprofitable profile weighed on sentiment.
- The stock is trading near the low end of its 52-week range after a prolonged multi-month downtrend.
- Commercial momentum around the OneRF ablation systems and the StereoCED drug-delivery platform remains a key watch item.
- For additional detail, explore NeuroOne's Price Targets, Earnings, and Forecast pages.
- Investors seeking automated strategies can also explore Trending AI Robots.
NeuroOne Medical Technologies (NMTC) Company Overview and Market Position
NeuroOne Medical Technologies Corporation is a medical technology company headquartered in Eden Prairie, Minnesota, focused on transforming the surgical diagnosis and treatment of neurological disorders. The company develops thin-film electrode technology used to record brain activity and to deliver radiofrequency ablation, serving patients with epilepsy, trigeminal neuralgia, and related conditions.
Its product portfolio includes the Evo Cortical and Evo sEEG diagnostic electrodes, the FDA-cleared OneRF Ablation System, and the OneRF Trigeminal Nerve Ablation System. The company is also advancing the StereoCED drug-delivery platform. NeuroOne has distribution relationships, including with large medtech partner Zimmer Biomet (ZBH), and clinical validation at major centers such as Mayo Clinic. Investors follow the stock for its commercial ramp in epilepsy and pain treatment, its international expansion potential, and its drug-delivery pipeline, while weighing those opportunities against continued operating losses.
NeuroOne Medical Technologies (NMTC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NMTC declined roughly 21.5%, falling from a closing price of about $1.12 to approximately $0.88. The move was not a single-day event but a steady grind lower punctuated by brief rebounds, reflecting sustained selling pressure rather than one isolated catalyst.
The broader trend over the last quarter has been firmly negative. From the start of September through early November, the stock fell from about $1.61 to roughly $0.88, a decline of around 45%, extending a longer downtrend that has carried the shares from a 52-week high near $6.12 toward the lower end of their 52-week range. This multi-month slide frames the recent 30-day move as part of a larger, ongoing repricing of the stock.
What Drove NMTC Stock Price in the Last 30 Days
The 30-day decline unfolded alongside a stream of company announcements that were operationally positive but failed to lift the share price. In early October, NeuroOne reported preliminary fiscal fourth-quarter product revenue growth of 38.4% and a record $4.5 million purchase order, with full-year product revenue up 15.6% to $10.5 million at the top of its guidance range. Later in the month, the company announced its first pharmaceutical-industry purchase order for the StereoCED drug-delivery platform, an NIH-backed research collaboration, and a peer-reviewed publication reporting favorable initial clinical results for the OneRF Trigeminal Nerve Ablation System.
Despite these developments, the shares continued to fall, suggesting that investor concerns outweighed the operational progress. NeuroOne remains unprofitable, with negative earnings per share and ongoing cash burn, and as a micro-cap name it carries elevated liquidity and dilution risk. Broader pressure on speculative, development-stage medtech stocks, combined with downward revisions to some analyst price targets, contributed to a sentiment backdrop in which positive clinical and commercial news was not enough to stabilize the stock.
What Drove NMTC Stock Performance Over the Last Quarter
Over the last quarter, NMTC extended a prolonged decline driven by a mix of structural and company-specific factors. The company completed a one-for-six reverse stock split in April 2026, and while product revenue has grown and order activity has improved, the business has continued to generate net losses. Investors have increasingly weighed the company's cash runway and potential for future dilution against its longer-term growth story.
The quarterly narrative has also been shaped by ongoing commercialization of the OneRF ablation systems, progress toward international certification such as ISO 13485, and early traction with the StereoCED drug-delivery platform. These milestones represent real strategic progress, but they have not yet translated into profitability, and the market has continued to price the stock as a high-risk, early-stage medical technology holding.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-driven trading bots. Tickeron offers hundreds of bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in this section. The bots vary widely in their approach, holding timeframes, and performance metrics, giving traders a way to compare different automated strategies across changing market conditions. For those looking to explore systematic approaches to trading names like NMTC and beyond, the page offers a practical starting point to review how these AI tools are currently positioned.
NMTC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors will be important for NMTC. First, the company's ability to convert its growing purchase-order backlog into recognized revenue and to improve gross margins will be a key indicator of commercial execution. Second, progress on international expansion, including the rollout enabled by its ISO 13485 certification and its distribution partnerships, could broaden the addressable market. Third, further clinical and commercial validation of the OneRF Trigeminal Nerve Ablation System and the StereoCED drug-delivery platform may influence both adoption and sentiment.
At the same time, investors should monitor the company's cash position, capital-raising activity, and path toward profitability, as these remain central risks for a loss-making micro-cap. Macroeconomic conditions, sector rotation within small-cap healthcare, and analyst expectations around upcoming earnings and guidance updates will also shape the near-term outlook. As with any early-stage medical technology company, the balance between clinical milestones and financial sustainability will be critical to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for NMTC turns negative, indicating new downward trend
NMTC saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 78 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NMTC entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMTC's RSI Indicator exited the oversold zone, 21 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 68 cases where NMTC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NMTC just turned positive on October 07, 2026. Looking at past instances where NMTC's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where NMTC advanced for three days, in 205 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
NMTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.124) is normal, around the industry mean (4.142). P/E Ratio (-0.977) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.260) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. NMTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices